Literature DB >> 26999490

Recent developments in second and third line therapy of metastatic renal cell carcinoma.

Maria Giuseppa Vitale1, Giacomo Cartenì1.   

Abstract

Entities:  

Keywords:  Cabozantinib; government funding; metastatic; nivolumab; renal cell cancer; second line; therapy; third line

Mesh：

Substances：

Year:  2016        PMID： 26999490     DOI： 10.1586/14737140.2016.1168696

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


× No keyword cloud information.
  8 in total

1.  Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool.

Authors:  Paul W Sperduto; Brian J Deegan; Jing Li; Krishan R Jethwa; Paul D Brown; Natalie Lockney; Kathryn Beal; Nitesh G Rana; Albert Attia; Chia-Lin Tseng; Arjun Sahgal; Ryan Shanley; William A Sperduto; Emil Lou; Amir Zahra; John M Buatti; James B Yu; Veronica Chiang; Jason K Molitoris; Laura Masucci; David Roberge; Diana D Shi; Helen A Shih; Adam Olson; John P Kirkpatrick; Steve Braunstein; Penny Sneed; Minesh P Mehta
Journal:  Neuro Oncol       Date:  2018-11-12       Impact factor: 12.300

2.  Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases.

Authors:  Paul W Sperduto; Brian J Deegan; Jing Li; Krishan R Jethwa; Paul D Brown; Natalie Lockney; Kathryn Beal; Nitesh G Rana; Albert Attia; Chia-Lin Tseng; Arjun Sahgal; Ryan Shanley; William A Sperduto; Emil Lou; Amir Zahra; John M Buatti; James B Yu; Veronica Chiang; Jason K Molitoris; Laura Masucci; David Roberge; Diana D Shi; Helen A Shih; Adam Olson; John P Kirkpatrick; Steve Braunstein; Penny Sneed; Minesh P Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-04-12       Impact factor: 7.038

Review 3.  Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma.

Authors:  Kevin Zarrabi; Shenhong Wu
Journal:  Curr Oncol Rep       Date:  2018-04-02       Impact factor: 5.075

Review 4.  New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy.

Authors:  Kevin Zarrabi; Chunhui Fang; Shenhong Wu
Journal:  J Hematol Oncol       Date:  2017-02-02       Impact factor: 17.388

Review 5.  Emerging therapeutic agents for genitourinary cancers.

Authors:  Kevin Zarrabi; Azzam Paroya; Shenhong Wu
Journal:  J Hematol Oncol       Date:  2019-09-04       Impact factor: 17.388

6.  Anti-4-1BB antibody-based combination therapy augments antitumor immunity by enhancing CD11c+CD8+ T cells in renal cell carcinoma.

Authors:  Seong-A Ju; Sang-Min Park; Yeonsoo Joe; Hun Taeg Chung; Won G An; Byung-Sam Kim
Journal:  Oncol Lett       Date:  2021-12-06       Impact factor: 2.967

Review 7.  Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.

Authors:  Prashanth Prithviraj; Nuzhat Ahmed; Revati Sharma; Elif Kadife; Mark Myers; George Kannourakis
Journal:  J Exp Clin Cancer Res       Date:  2021-06-07

8.  Cepharanthine Enhances TRAIL-Mediated Apoptosis Through STAMBPL1-Mediated Downregulation of Survivin Expression in Renal Carcinoma Cells.

Authors:  Sk Abrar Shahriyar; Seon Min Woo; Seung Un Seo; Kyoung-Jin Min; Taeg Kyu Kwon
Journal:  Int J Mol Sci       Date:  2018-10-22       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.